Aerogen creates 725 new jobs in Galway and Shannon

Aerogen, one of Ireland's prominent medical technology firms, has initiated an expansive growth plan projected to unfold over the next decade. This ambitious strategy, which entails an investment of €300 million, aims to bolster Aerogen’s research and development, manufacturing, and engineering initiatives. Headquartered in Galway, the company plans to tap into both local and international markets, while focusing heavily on developing technology aimed at assisting premature infants suffering from respiratory complications. A key product of Aerogen is the Aerogen Solo, which utilizes advanced vibrating mesh technology for effective respiratory care in diverse hospital environments. The investment from Enterprise Ireland has been instrumental in fortifying Aerogen's growth, enabling the firm to significantly scale its capabilities. Notably, the expansion effort has coincided with Aerogen reaching a remarkable milestone of treating its 25 millionth patient, affirming the impact and demand for its medical devices. In addition to improving current device technology, Aerogen is advancing its biopharmaceutical sector, including a partnership established in 2022 with a Chinese pharmaceutical company to innovate an inhaled vaccine for COVID-19. Furthermore, this job creation announcement aligns with broader employment growth trends in Ireland. According to the annual results released by Enterprise Ireland, overall employment within supported companies reached an unprecedented high, with significant growth recorded across various regions. The findings highlighted that most new jobs were generated outside Dublin, showcasing a robust employment landscape in different Irish counties. Companies in diverse sectors, including life sciences and agritech, contributed to this substantial growth despite economic challenges encountered globally. In light of this development, Aerogen's and Enterprise Ireland's leadership noted that the expansion serves as a vital indicator of the resilience and forward momentum of Irish-owned businesses in the medtech industry. With a global workforce projected to surpass 2,000 employees and a substantial proportion situated in Ireland, Aerogen is poised to significantly influence both the local economy and the health and wellness landscape on a global scale.